Cogent Biosciences Inc COGT:NASDAQ

Last Price$7.84Cboe Real-Time Last Sale as of 11:39AM ET 1/18/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.30(3.63%)
Bid (Size)$7.82 (4)
Ask (Size)$7.85 (100)
Day Low / High$7.81 - 8.12
Volume20.9 K
 

View Biotechnology IndustryPeer Comparison as of 01/18/2022

 

Cogent Biosciences Inc ( NASDAQ )

Price: $7.84
Change: -0.30 (3.63%)
Volume: 20.9 K
11:39AM ET 1/18/2022
 
 

Selecta Biosciences Inc ( NASDAQ )

Price: $2.62
Change: -0.15 (5.42%)
Volume: 222.2 K
11:41AM ET 1/18/2022
 
 

Jounce Therapeutics Inc ( NASDAQ )

Price: $6.13
Change: -0.15 (2.39%)
Volume: 217.4 K
11:37AM ET 1/18/2022
 
 

Verastem Inc ( NASDAQ )

Price: $1.73
Change: -0.07 (3.89%)
Volume: 295.0 K
11:41AM ET 1/18/2022
 
 

Cortexyme Inc ( NASDAQ )

Price: $9.89
Change: -0.79 (7.40%)
Volume: 302.8 K
11:34AM ET 1/18/2022
 

Read more news Recent News

HC Wainwright Starts Cogent Biosciences at Buy With $25 Price Target
6:46AM ET 10/11/2021 MT Newswires

Cogent Biosciences (COGT) has an average investment rating of buy and price targets ranging from $15 to $24, according to analysts polled by Capital IQ....

--Wedbush Adjusts Cogent Biosciences PT to $19 From $24, Maintains Outperform Rating
1:26PM ET 8/16/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Jefferies & Co Assumes Coverage on Cogent Biosciences With Buy Rating, $20 Price Target
11:50AM ET 6/09/2021 MT Newswires

Cogent Biosciences (COGT) has an average rating of Buy and price targets ranging from $15 to $24, according to analysts polled by Capital IQ. (MT Newswires...

--Wedbush Adjusts Price Target on Cogent Biosciences to $24 From $23, Keeps Outperform Rating
6:20AM ET 5/13/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. View company web site for more details
Address200 Cambridge Park Drive
Cambridge, Massachusetts 02140
Phone+1.617.945.5576
Number of Employees56
Recent SEC Filing01/04/20224
President, Chief Executive Officer & DirectorAndrew R. Robbins
Chief Financial & Accounting OfficerJohn L. Green
Chief Medical OfficerJessica Sachs
Chief Scientific OfficerJohn Robinson

Company Highlights

Price Open$8.12
Previous Close$8.13
52 Week Range$5.83 - 12.60
Market Capitalization$312.2 M
Shares Outstanding39.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/15/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$7.24
Beta vs. S&P 500N/A
Revenue$9.7 M
Net Profit MarginN/A
Return on Equity-26.94%

Analyst Ratings as of 10/08/2021

Buy
7
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset